CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive results from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, evaluating the ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the Phase 1 study of salanersen (ION306/BIIB115), an investigational antisense ...
Ionis is a promising biotech with a strong late-stage pipeline and lucrative Big Pharma partnerships, despite current weak commercial revenues and heavy losses. The company has five FDA-approved drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results